Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.

Volume: 191, Issue: 2, Pages: 131 - 139
Published: Aug 1, 2007
Abstract
Background The efficacy and safety of long-acting injectable risperidone have not been compared with those of an oral atypical antipsychotic. Aims To compare long-acting risperidone and oral olanzapine in 377 patients with DSM–IV schizophrenia or schizoaffective disorder. Method Patients were randomised to receive long-acting risperidone (25 mg or 50 mg every 14 days) or olanzapine (5–20 mg/day). Results In the 13-week phase, long-acting...
Paper Details
Title
Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study.
Published Date
Aug 1, 2007
Volume
191
Issue
2
Pages
131 - 139
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.